MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.nmd.2025.106278

Медицинская библиотека · Neuromuscular disorders : NMD · 2025

Dystrophinopathy in ACTION: The first 500 males enrolled in the Advanced Cardiac Therapies Improving Outcomes Network prospective dystrophinopathy registry.

Hayes Emily A, Villa Chet R, Kroslowitz Benjamin, Nandi Deipanjan, Cripe Linda, Soslow Jonathan H, Mokshagundam Deepa, Shih Renata, Wisotzkey Bethany, Parent John J, Cunningham Tyler, Conway Jennifer, Esteso Paul, Birnbaum Brian F, Shugh Svetlana B, Raucci Frank J, Kaufman Beth D, Soares Nelia, Kirmani Sonya, Martinez Hugo R, Gambetta Katheryn, Lal Ashwin K, Wittlieb-Weber Carol A

СтатьяПеревод в очереди

Аннотация

The Advanced Cardiac Therapies Improving Outcomes Network formed a dystrophinopathy registry to define cardiac diagnostics, management, and advanced therapies in the current era. Males with dystrophinopathy and one of the following: age ≥10 years, cardiomyopathy, or receipt of gene therapy, were eligible for enrollment. Data collection occurred at enrollment and every 6 months thereafter and includes demographics, neuromuscular, cardiac, and pulmonary endpoints, medications, advanced cardiac therapies, and outcomes. This analysis is of the first 500 males with a mean age of 18.1 years (± 5.38 years), the majority being white (81.2%) with Duchenne Muscular Dystrophy (91.4%), on glucocorticoids (80.2%), non-ambulatory (67.2%), and not requiring respiratory support (54.0%). In this cohort, 58.8% had evidence of cardiac involvement, 54.6% with evidence of ventricular dysfunction. The majority were on cardiac medication: 458 (91.6%) on angiotensin converting enzyme inhibitor or equivalent, 346 (69.2%) on mineralocorticoid receptor antagonist, and 264 (52.8%) on beta-blocker. One-hundred thirteen (22.6%) had an arrhythmia, 8 (1.6%) an implantable cardioverter defibrillator, 6 (1.2%) a ventricular assist device, and 3 (0.6%) underwent heart transplantation. Longitudinal data collection will establish a modern natural history of cardiomyopathy in dystrophinopathy, providing critical information to inform cardiac management and clinical trials.

Для цитирования: Hayes Emily A, Villa Chet R, Kroslowitz Benjamin, Nandi Deipanjan, Cripe Linda, Soslow Jonathan H, Mokshagundam Deepa, Shih Renata, Wisotzkey Bethany, Parent John J, Cunningham Tyler, Conway Jennifer, Esteso Paul, Birnbaum Brian F, Shugh Svetlana B, Raucci Frank J, Kaufman Beth D, Soares Nelia, Kirmani Sonya, Martinez Hugo R, Gambetta Katheryn, Lal Ashwin K, Wittlieb-Weber Carol A. Dystrophinopathy in ACTION: The first 500 males enrolled in the Advanced Cardiac Therapies Improving Outcomes Network prospective dystrophinopathy registry.. Neuromuscular disorders : NMD. 2025. DOI: 10.1016/j.nmd.2025.106278.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.